Table 1.
Baseline Characteristics by Sex
| Baseline Characteristics | Women (n=4416) | Men (n=13 728) |
|---|---|---|
| Age, y | 66 (58–74) | 63 (56–70) |
| Age ≥75 y | 947 (21) | 1851 (14) |
| Hypertension | 3093 (70) | 8044 (59) |
| Current smoker | 1290 (29) | 4688 (34) |
| Diabetes mellitus | 1407 (32) | 3526 (26) |
| History of CHF | 238 (5.4) | 552 (4.0) |
| History of coronary revascularization | 908 (21) | 3579 (26) |
| History of stroke or TIA | 316 (7.2) | 755 (5.5) |
| Peripheral arterial disease | 268 (6.1) | 737 (5.4) |
| CABG | 299 (6.8) | 1385 (10) |
| eGFR <60 ml/min/1.73 m2 | 1378 (32) | 2135 (16) |
| BMI, kg/m2 | 28 (24–32) | 28 (25–31) |
| Prior statin use | 1567 (36) | 4679 (34) |
| Prior lipid‐lowering agent use | 1607 (37) | 4827 (35) |
| At qualifying event | ||
| STEMI | 1036 (24) | 4154 (30) |
| NSTEMI | 2136 (48) | 6419 (47) |
| Unstable angina | 1239 (28) | 3147 (23) |
| LDL‐C <100 mg/dL | 2601 (60) | 7976 (59) |
| LDL‐C <70 mg/dL | 553 (13) | 1927 (14) |
| Statin | 3323 (75) | 10 703 (78) |
| At randomization | ||
| LDL‐C <100 mg/dL | 3345 (77) | 10 802 (80) |
| LDL‐C <70 mg/dL | 1343 (31) | 4448 (33) |
| Aspirin | 4231 (96) | 13 361 (97) |
| Thienopyridine | 3608 (82) | 12 074 (88) |
| Dual antiplatelet | 3498 (79) | 11 838 (86) |
Data presented are median (interquartile range) for continuous variables and number (percentage) for categorical variables. P<0.05 for all comparisons, except for BMI (P=0.1), NSTEMI at QE (P=0.058), and LDL‐C <100 mg/dL at QE (P=0.318). BMI indicates body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; LDL‐C, low‐density lipoprotein cholesterol; NSTEMI, non–ST‐segment–elevation myocardial infarction; STEMI, ST‐segment–elevation myocardial infarction; and TIA, transient ischemic attack.